Molsidomine

Summary

Molsidomine (CHEMBL1329455) is an approved small-molecule vasodilator agent (ATC C01DX12); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01DX12
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 242.23 Da · C9H14N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1329455
Name	Molsidomine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5353788
ChEBI	CHEBI:31861
ATC	C01DX12
Molecular formula	C9H14N4O4
Molecular weight	242.23
InChIKey	XLFWDASMENKTKL-UHFFFAOYSA-N

SMILES: CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-]

IUPAC name: (1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate

ChEBI definition: A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.

Pharmacological roles (ChEBI): vasodilator agent, antioxidant, nitric oxide donor, apoptosis inhibitor, cardioprotective agent.

Also known as: CAS 276, CAS-276, CAS276, Corvasal, Corvaton mite, Corvaton ret, Molsidomina, Molsidomine, Morsydomine, NSC-757398, SID11111444, SID50104240

Patent coverage: 4,486 distinct patent families (17,116 SureChEMBL compound mentions), from 4 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, Endonuclease 4, Thyroid hormone receptor beta, Beta-lactamase, Estrogen receptor, Muscarinic acetylcholine receptor M1, Cytochrome P450 3A4, Prostaglandin G/H synthase 1, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
THRB	7.9	Potency	12.6	nM	CHEMBL_ACT_4013891
HIF1A	6.5	Potency	316.2	nM	CHEMBL_ACT_4130588
HIF1A	6.5	Potency	316.2	nM	CHEMBL_ACT_4518865
CYP3A4	5.9	Potency	1259	nM	CHEMBL_ACT_4985713
CYP3A4	5.9	Potency	1259	nM	CHEMBL_ACT_5054702
LMNA	5.2	Potency	6310	nM	CHEMBL_ACT_3626073
P08482	5.1	Potency	7943	nM	CHEMBL_ACT_4853802
TDP1	5.05	Potency	8912	nM	CHEMBL_ACT_3930539
P0A6C1	5	Potency	10000	nM	CHEMBL_ACT_4084673

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00382421	Not specified	COMPLETED	Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).